MannKind Corp (MNKD) Reports Positive AFREZZA Phase 3 Results in Type 2 Diabetes
Tweet Send to a Friend
MannKind Corporation (Nasdaq: MNKD) announced positive preliminary results from Study 175, a Phase 3 clinical study of AFREZZA® (insulin human ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
